TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03552146
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
Study: NCT00003150
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003150
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01026792
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01496547
Drug: intensive chemo - RIC preparation
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
Study: NCT02221375
Drug: BHT low
Normalized name: BHT
DrugBank: Butylated hydroxytoluene (DB16863)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02221375
Drug: BHT medium
Normalized name: BHT
DrugBank: Butylated hydroxytoluene (DB16863)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02221375
Drug: BHT high
Normalized name: BHT
DrugBank: Butylated hydroxytoluene (DB16863)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02221375
Drug: BI 54903 XX low
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02221375
Drug: BI 54903 XX medium 1
Normalized name: Bis(1-piperidylthiocarbonyl) disulfide
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02221375
Drug: BI 54903 XX medium 2
Normalized name: Bis(2-benzothiazolyl) disulfide
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02221375
Drug: BI 54903 XX high
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02221375
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00631566
Drug: Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).~pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.~Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days.
Study: NCT02714959
Drug: Proleukin
Normalized name: Proleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000586
Drug: hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03384979
Drug: Iopamidol
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contrast agent will be adrministered intravenously using total body weight or lean body weight, calculated with bioelectrical impedance analysis balance.
Study: NCT03300479
Drug: Clevidipine
Normalized name: Clevidipine
DrugBank: Clevidipine (DB04920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous antihypertensive therapy with Clevidipine for the first 24 hours in patients with nontraumatic intracerebral hemorrhage (ICH).
Study: NCT03300479
Drug: Urapidil
Normalized name: urapidil
DrugBank: Urapidil (DB12661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: We compare the therapy with Urapidil to Clevidipine for the acute phase (24 hours) in patients with ICH. We would like to show the efficacy and safety of Clevidipine in this special situation.
Study: NCT00227955
Drug: Imipramine
Normalized name: Imipramine
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00472381
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin
Study: NCT03387046
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 1000 mg was administered intravenously once daily for 5 consecutive days.
Study: NCT01529112
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01529112
Drug: Lenvatinib matched placebo
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01529112
Drug: BSC
Normalized name: NHPBSC
DrugBank: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (DB15867)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04094805
Drug: Rocaltrol
Normalized name: Rocaltrol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocaltrol 0.25 μg daily for 1 month; HD-DXM (orally at 40 mg daily for 4d )
Study: NCT04094805
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HD-DXM (orally at 40 mg daily for 4d )
Study: NCT00118794
Drug: Chlorproguanil-dapsone (Lapdap)
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02487706
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir 50mg/day per 5 days
Study: NCT00197483
Drug: Pergolide (drug)
DrugBank: Pergolide (DB01186)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00357604
Drug: Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 28 days.
Study: NCT00357604
Drug: Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets + Capsules/Capsules, Oral, (25 mcg of EE + 0.18/0.215/0.25 mg of NGM) + 300/100 mg then 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 21 days.
Study: NCT04627753
Drug: Rituximab, lenalidomide
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance for 2 years
Study: NCT01522547
Drug: pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
Study: NCT01229553
Drug: decolonization
Normalized name: Profend Nasal Decolonization
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
Study: NCT00790933
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab intravenous infusion
Study: NCT05160285
Drug: Nivolumab 100 MG in 10 ML Injection
Normalized name: nivolumab 100 MG in 10 ML Injection
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: If you meet all the conditions to participate in the trial, you will receive the following treatments: Your physician will give you 360 mg of Nivolumab as an intravenous infusion every 3 weeks for about 30 minutes. For safety reasons, we recommend that you stay in the hospital for 60 minutes after the initial infusion of nivolumab. There will be a total of 3 cycles of Nivolumab treatments during the study period. You will need to return every 3 weeks. Each return will collect about 50 ml (10 tsp) of blood samples, depending on local standards.
Study: NCT00349076
Drug: 5-FU and oxaliplatin
Normalized name: 5-FU
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative radiochemotherapy:~Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours repeat day 15, 8 cycles
Study: NCT00829231
Drug: Sorafenib (Nexavar, BAY43-9006)
Normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mildly Hepatic Impaired Subjects
Study: NCT00829231
Drug: Sorafenib (Nexavar, BAY43-9006)
Normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderately Hepatic Impaired Subjects
Study: NCT00829231
Drug: Sorafenib (Nexavar, BAY43-9006)
Normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Healthy Subjects
Study: NCT00349076
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative radiochemotherapy:~5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles
Study: NCT04557137
Drug: Somatostatin analog
Normalized name: Somatostatin analog
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg ipstyl every 28 days
Study: NCT00363467
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mobilization Option 1:Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously.~Mobilization Option 2: If patients have recovered hematologically from consolidation chemotherapy, they may receive G-CSF at 10 mcg/kg twice daily subcutaneously.
Study: NCT00363467
Drug: Leukapheresis
Normalized name: autologous T lymphocytes obtained from peripheral blood lymphocytes by leukapheresis, transduced with a self-inactivating, non-replicating lentiviral vector, encoding a bispecific chimeric antigen receptor targeting CD19 and CD20
DrugBank: Prizloncabtagene autoleucel (DB18623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: leukapheresis
Study: NCT00363467
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2
Study: NCT00221325
Drug: Intraventricular Rituximab Plus MTX
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraventricular injection of rituximab into an Ommaya reservoir on day 1 of each week. Intraventricular rituximab plus methotrexate (MTX) on day 4 of each week.~First three patients at dose A : 25 mg rituximab on day 1, and MTX (12 mg) plus rituximab (10 mg) on day 4 each week.~If there are no dose limiting toxicities at Dose A in all of the first 3 patients or in 5 of the first 6 patients, the next 3 patients will receive dose level B: 25 mg rituximab on day 1, and combination MTX (12 mg) plus rituximab (25 mg) on day 4 of each week.~Oral leucovorin rescue 24 hours after each MTX administration. Maximum injections will be 16 over 9-weeks. Subjects who experience a partial response at week 10 will be given the option for extended dosing.
Study: NCT01272778
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsule, 0.2 mg, single acute dose
Study: NCT01272778
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral capsule, 0.5 mg, single acute dose
Study: NCT01272778
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral capsule, 1.0 mg, single acute dose
Study: NCT01272778
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral capsule, 2.0 mg, single acute dose
Study: NCT01341938
Drug: Commit® nicotine lozenges (4 mg) & self-help materials
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants provided with instructions on standard use of lozenge for nicotine replacement therapy (NRT) \& instructed to use the lozenge any time they have a craving or urge to use ST or tobacco. Dosing: weeks 1-6 one lozenge every 1-2 hours/16 per day, weeks 7-9 one lozenge every 2-4 hours/8 per day, weeks 10-12 one lozenge every 4-8 hours/4 per day + The Enough Snuff video and printed guide providing strategies for tobacco cessation.
Study: NCT02661373
Drug: SJ733
Normalized name: Tafenoquine
DrugBank: Tafenoquine (DB06608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single, multi, or boosted oral dose.
Study: NCT02661373
Drug: Cobicistat
Normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercially available cobicistat 150 mg tablets will be used. It will be administered as a single oral dose together with SJ733.
Study: NCT01913470
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.
Study: NCT00245570
Drug: Comparator: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 dose montelukast 10 mg tablet given orally in one of three treatment periods
Study: NCT00245570
Drug: Comparator: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 dose of 50 ug salmeterol given by inhalation in one of three treatment periods
Study: NCT00008333
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04285684
Drug: ketamine in lactation
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 dose IM by weight and assessing concentrations of ketamine in expressed milk at intervals
Study: NCT01975649
Drug: Tribulus Terrestris
Normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will use 750 mg/day during 120 days
Study: NCT00585585
Drug: betahistine dihydrochloride
Normalized name: Betahistine Dihydrochloride
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, 50-300 mg, daily
Study: NCT03794323
Drug: BI 764122
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00937911
Drug: YM150
Normalized name: Yohimbine
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03055221
Drug: Intravenous Treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.
Study: NCT04461535
Drug: Adrenocorticotropic hormone
Normalized name: Adrenocorticotropic hormone
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients divided into Intervention group need to undergo stimulation with a continuous cosyntropin infusion (50 μg/h started 30 minutes before sampling during AVS). Right and left adrenal venous blood and corresponding peripheral venous blood should be sampled sequentially.
Study: NCT02011464
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exparel is infiltrated into posterior compartment for pain control
Study: NCT00153920
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03191201
Drug: Ferric Carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.
Study: NCT03191201
Drug: 0.9% sodium chloride solution
Normalized name: Precedex 80mcg/20mL in 0.9% Sodium Chloride Solution for Injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mL of a commercially available sterile 0.9% sodium chloride solution.
Study: NCT05219656
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue therapy in acute severe ulcerative colitis
Study: NCT01014520
Drug: Gabapentin , Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, 300 mg, oral, single dose 2 hours before surgery~Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery
Study: NCT00045955
Drug: Fexofenadine, Comparator = Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02021604
Drug: Fluorodopa F 18
Normalized name: FLUORODOPA F-18
DrugBank: Fluorodopa (18F) (DB13848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
Study: NCT03908008
Drug: Botox (Botulinum toxin type A)
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
Study: NCT03908008
Drug: MT10107 (Botulinum toxin type A)
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
Study: NCT00604539
Drug: Chondroitin sulphate (Condrosan)
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg (two capsules of 400 mg each) taken once a day for one year
Study: NCT03967964
Drug: Dehydroepiandrosterone Oral Capsule
Normalized name: DEHYDROEPIANDROSTERONE
DrugBank: Prasterone (DB01708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule containing 25 mg DHEA
Study: NCT03418974
Drug: Pitavastatin
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.
Study: NCT03418974
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.
Study: NCT00710554
Drug: Sativex
Normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Study: NCT00841074
Drug: chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.12% chlorhexidine mouthwash spray, \~1.3 ml, twice a day.
Study: NCT01164956
Drug: methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00967798
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
Study: NCT01409564
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.
Study: NCT01036035
Drug: Tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of different dosages of drug
Study: NCT01036035
Drug: Pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of different dosages of drug
Study: NCT04615923
Drug: Pridopidine
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration: Oral~Dose: 45mg twice daily
Study: NCT00045500
Drug: 7-hydroxystaurosporine
Normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00045500
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03527095
Drug: FDL169
Normalized name: FDL169
DrugBank: FDL169 (DB16878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFTR corrector
Study: NCT02282020
Drug: OLAPARIB
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.
Study: NCT01685931
Drug: Paliperidone Palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
Study: NCT00785395
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up-down dosing determination
Study: NCT02244489
Drug: Momelotinib (MMB)
Normalized name: momelotinib
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib (MMB) tablet(s) administered orally once or twice daily